Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.60 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
1.55 1.65 1.60 1.60 1.60
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 3.14 -0.24 -0.07 6
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX

Byotrol (BYOT) Latest News

More Byotrol News
Byotrol Takeover Rumours

Byotrol (BYOT) Discussions and Chat

Byotrol Forums and Chat

Date Time Title Posts
31/7/201822:54Byotrol (BYOT) One to Watch on Wednesday -
27/2/201619:04Byotrol:::::::::Cleaning Up45
03/1/201309:22Byotrol - ready to tap a $5.6billion market?3,489

Add a New Thread

Byotrol (BYOT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-12-11 14:22:581.58100,0001,575.00O
2019-12-11 14:16:501.58320,6355,050.00O
2019-12-11 14:11:501.7020,000340.00O
2019-12-11 09:41:011.65100,0001,650.00O
View all Byotrol trades in real-time

Byotrol (BYOT) Top Chat Posts

Byotrol Daily Update: Byotrol Plc is listed in the Chemicals sector of the London Stock Exchange with ticker BYOT. The last closing price for Byotrol was 1.60p.
Byotrol Plc has a 4 week average price of 1.55p and a 12 week average price of 1.53p.
The 1 year high share price is 3.35p while the 1 year low share price is currently 1.50p.
There are currently 402,836,491 shares in issue and the average daily traded volume is 578,826 shares. The market capitalisation of Byotrol Plc is £6,445,383.86.
mudbath: Are we seeing the potential for a "triple bottom" in the BYOT share price chart? "What Does a Triple Bottom Tell You? The triple bottom chart pattern typically follows a prolonged downtrend where bears are in control of the market. While the first bottom could simply be normal price movement, the second bottom is indicative of the bulls gaining momentum and preparing for a possible reversal. The third bottom indicates that there's strong support in place and bears may capitulate when the price breaks through resistance levels." (Investopedia) If so(in the event of any subsequent reversal in the prolonged downtrend):- "The formation of triple bottom is seen as an opportunity to enter a bullish position."
sikhthetech: Read 1gw's post from rthm.. He and his mates DID EXACTLY the same at rthm with the well written plausible sounding optimistic post to entice readers in and then 1 week later and after a mere 4% rise in share price he sold some to reduce some losses.Classic Pump/dump. and it's not just a coincidence that 1gw's mate, spacedust appears this afternoon on TLY to endorse 1gw . rthm have long had questionable accounts/practices and an unproven model. ALWAYS DO YOUR OWN RESEARCH AND READ THE COMPANY/INDUSTRY NEWSFLOW. sikhthetech - 27 Apr 2018 - 20:31:17 - 7220 of 10009 RHYTHMONE - new Name, new Beginning??? - RTHM ONE week ago... well written post... Last Fri share price closed 210p today share price closed 220p up 10p or around 4%. and just 1 month before the results. I'm sure not many posters would post such resounding confidence and then ONE week later, when share price has hardly moved and no news, sell some. Didn't you believe your own optimism? 1gw - 19 Apr 2018 - 22:52:23 - 13673 of 13807 RhythmOne - 2016 a new beginning - RTHM Fleshed out optimism then. They have basically delivered over the last 2 years in my opinion. If you look at the trends they are exciting, albeit starting from a low base. If I have the numbers right, some key metrics are: Revenues: FY16 $167m FY17 $175m (including discontinued ops) FY18 $255m Adjusted EBITDA: FY16 -$10m FY17 +$1m FY18 +$14m Profit/Loss: FY16 -$92m FY17 -$19m FY18 -$?m {-$8m in 1H) Cash from operations: FY16 -$6m (Net cash used in operating activities) FY17 -$6m FY18 +$7m (corrected) If I then look at the specific "guidance" for FY18, a year ago, before RadiumOne and YuMe, they pointed to the "consensus" estimates of $220m revenue and $15.1m adjusted EBITDA. Revenue guidance Radium One did $20m in financial 2Q, so maybe $40m in 3Q+4Q, $60m for FY18. YuMe was doing around $40m/quarter, so maybe $25m in Feb-Mar So adding $220m+$60m+25m, you get to about $305m Even allowing for some closing down of "non-core" in RadiumOne and YuMe it seems they've come in a bit light on revenue compared to the original consensus. Adjusted EBITDA guidance RadiumOne was originally expected to be adj EBITDA neutral over the first 12 months, but then they said synergy delivery was behind schedule. So we can expect an adj EBITDA loss from RadiumOne in the FY18 numbers. YuMe was adjusted EBITDA profitable, so this would help to offset the RadiumOne loss. It seems to me they must have come close to guidance (adjusted for acquisitions) on adjusted EBITDA Plus they've done 2 major acquisitions in the year. So light on revenue, close on adjusted EBITDA and 2 acquisitions. But the acquisitions give them scale, so the revenue miss is outweighed (I would say) by the acquired revenue and improved profitability going forward. So I'd say a resounding success for FY18. Sort of guided, came reasonably close to guidance and also delivered 2 big acquisitions which vastly increase scale. Then on cash, they're actually significantly operating cashflow positive it appears, which would be a huge change and testament (so far) to the logic of the scale-giving acquisitions. But the real reason for optimism is the actual guidance for FY19. No longer just pointing to consensus but stating that they believe they "are well-positioned to deliver a further strong performance in FY2019 - fully in line with current consensus estimates in market" And as others have posted market estimates (Whitman Howard, Numis) are mouth-watering. And all that against the background of a huge sell off in the share price over the last year - which must have left many shareholders fearing that the TU would reveal an obvious (in hindsight) reason for the sell off. How's that for considered optimism? .No advice intended of course and please do your own research. 1gw - 27 Apr 2018 - 15:19:12 - 13805 of 16477 RhythmOne - 2016 a new beginning - RTHM I've taken some off the table at just over 2.20, selling the number that I bought on 9th April at 1.62. That gives me a good profit on that purchase or is about breakeven on the weighted average price of the 3 purchases I've made since the merger completed. Brings my R1 holding down a bit but still one of my top 2 holdings.
mudbath: If the fact that MMs are bidding a good premium for a million shares constitutes a bullish signal then we might expect further progress in the BYOT share price. Ghost The main factor that should help the stock over coming months is its apparent woefull undervaluation at the recently upwardly revised 1.80 pence.Any positive future developments will serve to further improve sentiment. As Thunderclap Newman once said (is there),"Something in the Air" ?
sikhthetech: 1gw, "The comparison with tly is relevant because of the similarity of the acquisition model," That's exactly my point and what I was saying... you use 'original contingency to state TLY fell short of expectations', yet on here you refer to potential of BYOT's acquisition.. and in your usual devious way, you change your view and, with your smooth posts, make it seem as if your view hasn't changed...your ego get's in the way, eh? But good to see you finally agree with the acquisition model being similar I mentioned the similarity in the acquisition model on the TLY but then you went quiet after I posted this, strange wasn't it, 1gw? sikhthetech - 07 Jun 2019 - 20:42:42 - 9223 of 10490 Totally Health - 2014 onwards - TLY 1gw, There's this company who specialise in disinfectant cleaners... you may have heard of them... Byotrol (BYOT).. They bought Medimark, nearly a yr ago as follows..: 1) Initial consideration of £2.3m 2) £0.4m Medimark debt 3) £1.15m cash 4) £1.15m from additional shares @ 4.1p 5) £1.8m deferred subject to achieving EBIDTA targets... Total consideration £4.5m for a company making ADJUSTED EBITDA of ONLY £380k on revenues of just £2.7m... using a similar strategy as TLY. "year ended 31 March 2018, Medimark reported adjusted EBITDA of GBP380k on revenues of GBP2.7m." "Consideration of up to GBP4.5m is payable in respect of the Acquisition, which includes GBP0.4m of debt that Byotrol is assuming.. Initial consideration of GBP2.3m is payable on completion, being GBP1.15m in cash and GBP1.15m from 28,048,780 new ordinary shares ("Ordinary Shares") being issued at 4.1p per share. An additional GBP1.8m of consideration is payable subject to achieving EBITDA targets in FYE 31 March 2019 and FYE March 2020. The deferred consideration is also to be paid half in cash and half in new ordinary shares." The placing price @ 4.1p, the current share price is around 50% lower @ 2.1p. Your ONE post on the acquisition, on the day of acquisition announced: 1gw - 23 Aug 2018 - 13:10:33 - 3152 of 3628 BYOTROL-CAN DELIVER AMAZING RESULTS - BYOT Nice surprise on my return from the beach! Good to see them get the results out today in the end and I like the fact that the acquisition shares are priced above 4p. Also I agree it sounds like good news that the Target trial is being extended - although I suppose it could mean the results are borderline and they need more time to decide whether it is going to be viable. Didn't you look at the accounts, liabilities, strategy etc, before loading up... Oh you did. Management seem to be doing the right thing, eh... Management seem to be doing the right things... 1gw - 28 Feb 2019 - 15:04:42 - 3455 of 3628 BYOTROL-CAN DELIVER AMAZING RESULTS - BYOT I've bought some more. Takes Byotrol into the top 3 in my portfolio. High risk, but management seem to be doing the right things and sound confident. I think there is potential for the share price to do very well, especially if they can derisk the US by landing some licensing deals now that they've got such a good shop window through the Target trial.
mudbath: With the chart looking as though the share price might be about to go higher,would anyone venture to hazard a guess at the BYOT share price on BREXIT day or October 31st 2019? I could see 3.75p being achievable.
mudbath: Byotrol 24 continues to churn out remarkable content on its US orientated Facebook pages. Generating a stream of proactive input of this quality takes talent. What an opportunity Byotrol,here in the UK,are passing up by not incorporating these eye catching promotions into their own blogs,twitter feed, etc. At least Medimark are "bigging up" their achievements on an almost daily basis. The BYOT share price looks poised to move significantly higher.
mudbath: A significant 928,089 delayed buy trade underlines my current view that the BYOT share price could well swiftly move above 3 pence and beyond. Byotrol's engagement of Alex Espalin (Ex product launch man at Kimberly-Clark Corporation)looks to be inspired,having regard to the speed with which he has overseen the EPA approval being gained and the introduction of Byotrol 24 across a growing number of TARGET stores,not to mention his stimulating the interest of other retailers in the product. This compares extremely favourably with Tristel's similar US endevours where they have spent 5 YEARS gaining EPA regulatory approval,only to issue the following statement alongside last weeks Interim Results :- "Furthermore, we have decided that our most prudent approach is to postpone commercialising the EPA approvals already obtained for our Duo and Jet products until we have greater visibility of the way ahead for the FDA project."..... "Conferring with consultants, peer companies and industry experts, we are led to believe that we should not be dismayed by the time it has taken to reach the point we are at today; nor by the cumulative cost, which amounted at 31 December 2018 to GBP1.3m." Byotrol/Medimark Scientific look poised to make inroads into Tristel's markets. Happy days !
mudbath: Investing is all about timing and if anyone missed the opportunity to mop up those Ruffer shares @ just 1.50 pence then fear not,for BYOT remain a total steal at today's 2.40 pence to buy.Remember that Medimark Scientific was purchased with Byotrol shares valued at 4.10 pence and with cash,also raised @ 4.0 pence. Listening to the vibes it looks as though BYOT are on something of a roll at the moment,with the market due to be appraised of progress in an upcoming trading update. It seems logical,to me,that the BYOT share price will soon resume its upward trajectory;maybe even in a vigorous fashion. BUY. NOW !!
mudbath: It looks as though the BYOT share price is about to move back towards fair value at a rate of knots, now that Ruffer have curtailed the recent dumping of the majority of their holding at that ludicrous 1.55 pence level. Nevertheless, Ruffer still hold 21 million shares,which could yet lead to future weakness if they intend to fully exit their position.
mudbath: After all,the conclusion of Byotrol's interim report read, "The recent fund raising of £4.6m, net of expenses, has given us the financial resources to grow and has secured some first-class new investors on our shareholder register. Our challenge now is to execute the commercial plan and deliver to the financial targets. The team is confident it will do so and looks forward to substantial progress in the second half of the financial year. We continue to look to our long-term future with confidence and excitement." The perverse market reaction to this most positive of statements was to take the BYOT share price down to its lowest ever level. It looks as though the market is now reconsidering the potential for Byotrol to shed its status as a "jam tomorrow company";hence the initial start of an upward movement in the SP,which might just evolve into an upward re rating of some significance.
Byotrol share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191212 09:11:43